Current Report Filing (8-k)
June 28 2019 - 05:16PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of
The Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): June 24,
2019
Outlook Therapeutics,
Inc.
(Exact name of registrant as specified in its charter)
Delaware |
001-37759 |
38-3982704 |
(State or other
jurisdiction
of incorporation) |
(Commission File
Number) |
(IRS Employer
Identification No.) |
7 Clarke Drive
Cranbury, New Jersey
|
08512 |
(Address of principal
executive offices) |
(Zip Code) |
Registrant's telephone number, including area code: (609)
619-3990
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant
under any of the following provisions:
|
¨ |
Written communications
pursuant to Rule 425 under the Securities Act (17 CFR
230.425) |
|
¨ |
Soliciting material
pursuant to Rule 14a-12 under the Exchange Act (17 CFR
240.14a-12) |
|
¨ |
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17
CFR 240.14d-2(b)) |
|
¨ |
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17
CFR 240.13e-4(c)) |
Securities pursuant to Section 12 (b) of the Act:
Title of Each Class |
|
Trading Symbol(s) |
|
Name of Each Exchange on Which
Registered |
Common
Stock |
|
OTLK |
|
The Nasdaq Stock
Market LLC |
Series A
Warrants |
|
OTLKW |
|
The Nasdaq Stock
Market LLC |
Indicate by check mark whether the registrant is an emerging growth
company as defined in Rule 405 of the Securities Act of 1933
(§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange
Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company x
If an emerging growth company, indicate by check mark if the
registrant has elected not to use the extended transition period
for complying with any new or revised financial accounting
standards provided pursuant to Section 13(a) of the Exchange Act.¨
x
|
Item 5.02 |
Departure of Directors or Certain Officers; Election of
Directors; Appointment of Certain Officers; Compensatory
Arrangements of Certain Officers. |
On June 24, 2019, Pankaj Mohan, Ph.D., notified Outlook
Therapeutics, Inc. (the “ Company ”) of his decision not to
stand for re-election to the Board of Directors of the Company (the
“ Board ”) at the 2019 annual meeting of stockholders of the
Company (the “ Annual Meeting ”), and his resignation as a
Class III director will be effective at the end of his current term
at the Annual Meeting. Dr. Mohan indicated that his decision not to
stand for re-election and his resignation from the Board was not a
result of any disagreement with the Company on any matter relating
to the Company’s operations, policies or practices.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of
1934, the registrant has duly caused this report to be signed on
its behalf by the undersigned hereunto duly authorized.
|
Outlook Therapeutics, Inc.
|
Date:
June 28, 2019 |
By: |
/s/
Lawrence A. Kenyon |
|
|
Lawrence A. Kenyon
Chief Executive Officer and Chief Financial Officer |
Outlook Therapeutics (NASDAQ:OTLK)
Historical Stock Chart
From Dec 2020 to Jan 2021
Outlook Therapeutics (NASDAQ:OTLK)
Historical Stock Chart
From Jan 2020 to Jan 2021